Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y.
The aim of this work is to investigate whether clomipramine (CIM) and lithium chloride (LiCl) potentiate the cytotoxicity of vinorelbine (VNR) on SH-SY5Y human neuroblastoma cells in vitro and whether midkine (MK) can be a resistance factor for these treatments. Four groups of experiments were performed for 96 h using both monolayer and spheroid cultures of SH-SY5Y cells: (1) control group, (2) singly applied VNR, CIM, and LiCl, (3) VNR with CIM, and (4) VNR with LiCl. Their effects on monolayer and spheroid cultures were determined by evaluating cell proliferation, bromodeoxyuridine labeling index (BrdU-LI), apoptosis, cyclic adenosine monophosphate (cAMP) and midkine levels, colony-forming efficiency, spheroid size, and ultrastructure. In comparison with the control group, single and combination drug treatments significantly reduced the proliferation index (PI) for 96 h. The most potent reduction of PI was observed with VNR in combination with CIM and LiCl for all time intervals. VNR with CIM and LiCl seemed to be ineffective in reducing BrdU-LI of both monolayer cell and spheroid cultures, spheroid size, and cAMP level. VNR with LiCl increased apoptosis at 24 h, however VNR with CIM increased apoptosis at 96 h. VNR was the most potent drug in inhibiting colony-forming efficiency. The combination of VNR with CIM was the most potent in reducing midkine levels among all groups. Interestingly, the combination of VNR with LiCl led to both nuclear membrane breakdown and disappearance of the cellular membranes inside the spheroids. Both CIM and LiCl seemed to potentiate VNR-induced cytotoxicity, and MK was not a resistance factor for VNR, LiCl, and CIM.
Bilir
Ayhan
A
Department of Histology and Embryology, Faculty of Medicine, Istanbul University, Istanbul, Turkey. bilira@istanbul.edu.tr
Erguven
Mine
M
Yazihan
Nuray
N
Aktas
Esin
E
Oktem
Gulperi
G
Sabanci
Akin
A
D000928:Antidepressive Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001973:Bromodeoxyuridine / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002997:Clomipramine / Q000494:pharmacology*; D000242:Cyclic AMP / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004357:Drug Synergism; D005434:Flow Cytometry; D006801:Humans; D018021:Lithium Chloride / Q000494:pharmacology*; D046529:Microscopy, Electron, Transmission / Q000379:methods; D000078792:Midkine; D014411:Neoplastic Stem Cells / Q000187:drug effects; D009447:Neuroblastoma / Q000473:pathology / Q000648:ultrastructure; D013997:Time Factors; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077235:Vinorelbine
D000928:Antidepressive Agents; D000972:Antineoplastic Agents, Phytogenic; D016207:Cytokines; D000078792:Midkine; D014747:Vinblastine; D000242:Cyclic AMP; D001973:Bromodeoxyuridine; D018021:Lithium Chloride; D002997:Clomipramine; D000077235:Vinorelbine
Expert Opin Ther Pat. 2009 Apr;19(4):475-91
19441927
Anticancer Res. 2007 Jan-Feb;27(1A):45-53
17352215
Neuro Oncol. 2008 Oct;10(5):690-9
18715951
Curr Biol. 2007 Jan 9;17(1):85-91
17208191
Brain Res. 2003 Dec 19;994(1):73-80
14642450
J Transl Med. 2009 Feb 05;7:13
19196452
J Mol Neurosci. 2005;27(1):29-42
16055945
Adv Drug Deliv Rev. 2009 Aug 10;61(10):850-62
19422869
Drugs. 1990 Jan;39(1):136-53
2178909
Pediatr Blood Cancer. 2009 Oct;53(4):590-3
19533657
Nat Rev Cancer. 2003 Mar;3(3):203-16
12612655
Acta Neurochir (Wien). 2003 Aug;145(8):683-90
14520549
J Neurochem. 1999 Nov;73(5):2084-92
10537068
Neuron. 2009 Jun 11;62(5):683-94
19524527
Hematol Oncol Clin North Am. 2010 Feb;24(1):65-86
20113896
Biochem Biophys Res Commun. 2005 Mar 11;328(2):623-32
15694394
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):107-22
11033301
Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34
19101580
Development. 1997 Mar;124(6):1099-107
9102297
Cancer Res. 1983 Feb;43(2):556-60
6848179
Neoplasma. 2002;49(1):38-42
12044058
Br J Cancer. 2009 Nov 3;101(9):1585-95
19809435
Cancer Lett. 2009 Jul 8;279(2):137-44
19250738
Cancer Sci. 2005 Jan;96(1):54-6
15649256
J Physiol Sci. 2006 Jun;56(3):247-51
16839461
Biochem Biophys Res Commun. 2009 Feb 6;379(2):434-9
19116135
Biol Reprod. 2002 Oct;67(4):1043-51
12297516
Int J Neuropsychopharmacol. 2008 Jun;11(4):533-9
18205980
Clin Cancer Res. 2009 Mar 1;15(5):1593-600
19223492
Eur J Pharmacol. 2009 Dec 25;625(1-3):174-80
19836384
J Biochem. 2002 Sep;132(3):359-71
12204104
Cancer Chemother Pharmacol. 2009 Oct;64(5):1053-8
19597728
Curr Med Chem. 2009;16(15):1917-48
19442155
Apoptosis. 1999 Feb;4(1):47-58
14634295
Oncol Rep. 2003 Mar-Apr;10(2):411-4
12579281
Cancer Res. 1995 Apr 15;55(8):1792-7
7712489
J Pharmacol Sci. 2009 May;110(1):14-28
19423950
World J Gastroenterol. 2008 Jan 7;14(1):76-80
18176965
Br J Cancer. 2003 May 19;88(10):1522-6
12771916
Mol Cell Endocrinol. 1999 Mar 25;149(1-2):71-7
10375019
Hepatobiliary Pancreat Dis Int. 2010 Feb;9(1):69-77
20133233
Curr Opin Investig Drugs. 2009 Dec;10(12):1269-79
19943199
Pediatr Clin North Am. 2008 Feb;55(1):97-120, x
18242317
Arch Iran Med. 2008 Nov;11(6):639-48
18976035
Cancer Sci. 2009 Sep;100(9):1735-9
19538527
Cancer. 2006 Aug 15;107(4):864-73
16832814
Clin Cancer Res. 2008 Mar 1;14(5):1540-9
18316579
Cancer Lett. 2004 Feb 20;204(2):127-43
15013213
Int J Cancer. 2009 Apr 1;124(7):1700-6
19089915
Neurochem Int. 2001 Jun;38(7):573-9
11290382
Bipolar Disord. 2009 Jun;11 Suppl 2:4-9
19538681
Neurochem Res. 2009 Mar;34(3):453-62
18688712
Oncol Rep. 2009 Oct;22(4):773-9
19724855
Int J Oncol. 2008 Apr;32(4):829-39
18360710
Mol Nutr Food Res. 2009 Jan;53(1):9-28
19123183
Science. 1956 Feb 24;123(3191):309-14
13298683